Physician profile
Joseph B Sappington
NPI 1285629410
$8,768.16
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $828 · 2021: $6,636 · 2022: $87.04 · 2023: $344 · 2024: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,093.75 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $387.70 | 2019-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $370.11 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $357.20 | 2019-2024 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $296.43 | 2019-2023 | Xarelto |
| Pfizer INC. | $274.71 | 2019-2024 | |
| Medtronic Vascular, INC. | $229.98 | 2020 | |
| Abbott Laboratories | $130.05 | 2019 | |
| Terumo Medical Corporation | $127.78 | 2020 | |
| Arbor Pharmaceuticals, INC. | $126.10 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.29 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $65.17 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $60.12 | 2021-2023 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $48.87 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $23.05 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $22.64 | 2023 | Onpattro |
| Lantheus Medical Imaging, INC. | $20.59 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $19.88 | 2023 | Inpefa |
| Amgen INC. | $15.75 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Sappington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.